http://protraderdaily.com/register/

At the close of the Canadian markets on Wednesday, September 13, 2017, the Toronto Exchange Composite index ended the trading session at 15,126.81, 0.11% lower from its previous closing price.

The Healthcare Index was also in the red, closing the day at 63.93, down 1.28%.

Pro-Trader Daily's complimentary research reports on the following stocks are now available: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

BELLUS Health Inc.

Laval, Canada-based BELLUS Health Inc.'s stock fell 2.78% to finish Wednesday's session at $0.35 with a total volume of 54,736 shares traded. BELLUS Health's shares have gained 29.63% in the past one year. The Company's shares are trading below its 50-day moving average of $0.37. Shares of the Company, which engages in developing novel therapeutics for conditions with high unmet medical need, are trading at a PE ratio of 87.50. See our research report on BLU.TO at:

http://protraderdaily.com/optin/?symbol=BLU

Helius Medical Technologies Inc.

On Wednesday, shares in Newtown, Pennsylvania headquartered Helius Medical Technologies Inc. recorded a trading volume of 90,374 shares, which was above their three months average volume of 64,939 shares. The stock ended the day 9.80% higher at $2.80. Helius Medical Technologies' stock has gained 8.95% in the last one month and 37.25% in the previous three months. Furthermore, the stock has rallied 112.12% in the past one year. Shares of the Company, which focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma in the US, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $2.58 is above its 200-day moving average of $2.18. The complimentary research report on HSM.TO at:

http://protraderdaily.com/optin/?symbol=HSM

Resverlogix Corp.

On Wednesday, shares in Calgary, Canada headquartered Resverlogix Corp. ended the session 2.13% higher at $1.44 with a total volume of 13,264 shares traded. Resverlogix's shares have gained 11.63% in the past one month. Shares of the Company, which develops small molecule therapeutics for bromodomain and extra-terminal inhibition in the US and Canada, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $1.76 is greater than its 50-day moving average of $1.38. Register for free and access the latest research report on RVX.TO at:

http://protraderdaily.com/optin/?symbol=RVX

Crescita Therapeutics Inc.

Shares of Mississauga, Canada headquartered Crescita Therapeutics Inc., which provides over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, closed the day 7.14% higher at $0.60. The stock recorded a trading volume of 12,144 shares at the end of Wednesday's session. Get free access to your research report on CTX.TO at:

http://protraderdaily.com/optin/?symbol=CTX

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 475382

"/> Report Coverage on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics « MarketersMedia – Press Release Distribution Services – News Release Distribution Services

Report Coverage on Healthcare Stocks, BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics

LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Biotechnology industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. Register for these free reports at:

http://protraderdaily.com/register/

At the close of the Canadian markets on Wednesday, September 13, 2017, the Toronto Exchange Composite index ended the trading session at 15,126.81, 0.11% lower from its previous closing price.

The Healthcare Index was also in the red, closing the day at 63.93, down 1.28%.

Pro-Trader Daily's complimentary research reports on the following stocks are now available: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

BELLUS Health Inc.

Laval, Canada-based BELLUS Health Inc.'s stock fell 2.78% to finish Wednesday's session at $0.35 with a total volume of 54,736 shares traded. BELLUS Health's shares have gained 29.63% in the past one year. The Company's shares are trading below its 50-day moving average of $0.37. Shares of the Company, which engages in developing novel therapeutics for conditions with high unmet medical need, are trading at a PE ratio of 87.50. See our research report on BLU.TO at:

http://protraderdaily.com/optin/?symbol=BLU

Helius Medical Technologies Inc.

On Wednesday, shares in Newtown, Pennsylvania headquartered Helius Medical Technologies Inc. recorded a trading volume of 90,374 shares, which was above their three months average volume of 64,939 shares. The stock ended the day 9.80% higher at $2.80. Helius Medical Technologies' stock has gained 8.95% in the last one month and 37.25% in the previous three months. Furthermore, the stock has rallied 112.12% in the past one year. Shares of the Company, which focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma in the US, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $2.58 is above its 200-day moving average of $2.18. The complimentary research report on HSM.TO at:

http://protraderdaily.com/optin/?symbol=HSM

Resverlogix Corp.

On Wednesday, shares in Calgary, Canada headquartered Resverlogix Corp. ended the session 2.13% higher at $1.44 with a total volume of 13,264 shares traded. Resverlogix's shares have gained 11.63% in the past one month. Shares of the Company, which develops small molecule therapeutics for bromodomain and extra-terminal inhibition in the US and Canada, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $1.76 is greater than its 50-day moving average of $1.38. Register for free and access the latest research report on RVX.TO at:

http://protraderdaily.com/optin/?symbol=RVX

Crescita Therapeutics Inc.

Shares of Mississauga, Canada headquartered Crescita Therapeutics Inc., which provides over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, closed the day 7.14% higher at $0.60. The stock recorded a trading volume of 12,144 shares at the end of Wednesday's session. Get free access to your research report on CTX.TO at:

http://protraderdaily.com/optin/?symbol=CTX

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 475382

LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the Biotechnology industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics. Register for these free reports at:

http://protraderdaily.com/register/

At the close of the Canadian markets on Wednesday, September 13, 2017, the Toronto Exchange Composite index ended the trading session at 15,126.81, 0.11% lower from its previous closing price.

The Healthcare Index was also in the red, closing the day at 63.93, down 1.28%.

Pro-Trader Daily's complimentary research reports on the following stocks are now available: BELLUS Health Inc. (TSX: BLU), Helius Medical Technologies Inc. (TSX: HSM), Resverlogix Corporation (TSX: RVX), and Crescita Therapeutics Inc. (TSX: CTX). Sign up now for your free membership and research reports at:

http://protraderdaily.com/register/

BELLUS Health Inc.

Laval, Canada-based BELLUS Health Inc.'s stock fell 2.78% to finish Wednesday's session at $0.35 with a total volume of 54,736 shares traded. BELLUS Health's shares have gained 29.63% in the past one year. The Company's shares are trading below its 50-day moving average of $0.37. Shares of the Company, which engages in developing novel therapeutics for conditions with high unmet medical need, are trading at a PE ratio of 87.50. See our research report on BLU.TO at:

http://protraderdaily.com/optin/?symbol=BLU

Helius Medical Technologies Inc.

On Wednesday, shares in Newtown, Pennsylvania headquartered Helius Medical Technologies Inc. recorded a trading volume of 90,374 shares, which was above their three months average volume of 64,939 shares. The stock ended the day 9.80% higher at $2.80. Helius Medical Technologies' stock has gained 8.95% in the last one month and 37.25% in the previous three months. Furthermore, the stock has rallied 112.12% in the past one year. Shares of the Company, which focuses on the development of products for the treatment of neurological symptoms caused by disease or trauma in the US, are trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $2.58 is above its 200-day moving average of $2.18. The complimentary research report on HSM.TO at:

http://protraderdaily.com/optin/?symbol=HSM

Resverlogix Corp.

On Wednesday, shares in Calgary, Canada headquartered Resverlogix Corp. ended the session 2.13% higher at $1.44 with a total volume of 13,264 shares traded. Resverlogix's shares have gained 11.63% in the past one month. Shares of the Company, which develops small molecule therapeutics for bromodomain and extra-terminal inhibition in the US and Canada, are trading above its 50-day moving average. Furthermore, the stock's 200-day moving average of $1.76 is greater than its 50-day moving average of $1.38. Register for free and access the latest research report on RVX.TO at:

http://protraderdaily.com/optin/?symbol=RVX

Crescita Therapeutics Inc.

Shares of Mississauga, Canada headquartered Crescita Therapeutics Inc., which provides over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, closed the day 7.14% higher at $0.60. The stock recorded a trading volume of 12,144 shares at the end of Wednesday's session. Get free access to your research report on CTX.TO at:

http://protraderdaily.com/optin/?symbol=CTX

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email contact@protraderdaily.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: contact@protraderdaily.com

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily

ReleaseID: 475382

Source URL: https://marketersmedia.com/report-coverage-on-healthcare-stocks-bellus-health-helius-medical-technologies-resverlogix-and-crescita-therapeutics/239330

Source: AccessWire

Release ID: 239330


Latest News